

Publications Related to the AIC NMR Facility

2001–2005

2005

1. Witte, R.P. and W.Y.J. Kao, *Keratinocyte-fibroblast paracrine interaction: the effects of substrate and culture condition*. *Biomaterials*, 2005. **26**(17): p. 3673–3682.
2. Ju, J., et al., *Migrastatin and dorrigocins are shunt metabolites of iso-migrastatin*. *Journal of the American Chemical Society*, 2005. **127**(6): p. 1622–1623.
3. Haug, B.E., M. Brewer, and D.H. Rich, *Facile degradative lactonization of Gln-Arg and Gln-Phe hydroxyethylene dipeptide derivatives*. *Journal of Peptide Research*, 2005. **65**(1): p. 77–83.
4. Comstock Lindsay, R. and R. Rajski Scott, *Conversion of DNA methyltransferases into azidonucleosidyl transferases via synthetic cofactors*. *Nucleic acids research*, 2005. **33**(5): p. 1644–52.

2004

1. Zilinski, J.L. and W.J. Kao, *Tissue adhesiveness and host response of in situ photopolymerizable interpenetrating networks containing methylprednisolone acetate*. *J Biomed Mater Res A*, 2004. **68**(2): p. 392–400.
2. Witte, R.P., et al., *Analysis of poly(ethylene glycol)-diacrylate macromer polymerization within a multicomponent semi-interpenetrating polymer network system*. *J Biomed Mater Res*, 2004. **71A**(3): p. 508–18.
3. Weller, R.L. and S.R. Rajski, *Aziridination of g,d-dibromoethyl-2-pentenoate with primary amines: extension of the Gabriel-Cromwell reaction*. *Tetrahedron Letters*, 2004. **45**(30): p. 5807–5810.
4. Sukonpan, C., et al., *Synthesis of substrates and inhibitors of botulinum neurotoxin type A metalloprotease*. *Journal of Peptide Research*, 2004. **63**(2): p. 181–193.
5. Ju, J., et al., *Conversion of (2S)-arginine to (2S,3R)-capreomycin by VioC and VioD from the viomycin biosynthetic pathway of Streptomyces sp. strain ATCC11861*. *Chembiochem*, 2004. **5**(9): p. 1281–5.
6. Jette, K.K., et al., *Preparation and Drug Loading of Poly(Ethylene Glycol)-block-Poly(ϵ -Caprolactone) Micelles Through the Evaporation of a Cosolvent Azeotrope*. *Pharmaceutical Research*, 2004. **21**(7): p. 1184–1191.
7. Hoang, K.C. and S. Mecozzi, *Aqueous solubilization of highly fluorinated molecules by semifluorinated surfactants*. *Langmuir*, 2004. **20**(18): p. 7347–7350.

8. Hoang, K. and S. Mecozzi, *Encapsulation of highly fluorinated drugs by semifluorinated block copolymers*. Polymer Preprints (American Chemical Society, Division of Polymer Chemistry), 2004. **45**(1): p. 965–966.
9. Haug, B.E. and D.H. Rich, *Synthesis of a Gln-Phe Hydroxy-ethylene Dipeptide Isostere*. Organic Letters, 2004. **6**(25): p. 4783–4786.
10. Goncalves, E., R.J. Debs, and T.D. Heath, *The effect of liposome size on the final lipid/DNA ratio of cationic lipoplexes*. Biophys J, 2004. **86**(3): p. 1554–63.
11. Ding, X., T.C. Stringfellow, and J.R. Robinson, *Self-association of cromolyn sodium in aqueous solution characterized by nuclear magnetic resonance spectroscopy*. Journal of Pharmaceutical Sciences, 2004. **93**(5): p. 1351–1358.
12. Ding, X., et al., *Oral absorption enhancement of cromolyn sodium through noncovalent complexation*. Pharmaceutical Research, 2004. **21**(12): p. 2196–2206.
13. Comstock, L.R. and S.R. Rajski, *Efficient Synthesis of Azide-Bearing Cofactor Mimics*. Journal of Organic Chemistry, 2004. **69**(4): p. 1425–1428.
14. Brewer, M., C.A. James, and D.H. Rich, *Synthesis of a tripeptide derivative containing the gln-arg hydroxyethylene dipeptide isostere*. Organic Letters, 2004. **6**(25): p. 4779–82.
15. Adams, M. and G.S. Kwon, *Spectroscopic investigation of the aggregation state of amphotericin B during loading, freeze-drying, and reconstitution of polymeric micelles*. Journal of Pharmacy & Pharmaceutical Sciences, 2004. **7**(4): p. 1–6.

2003

1. Yang, J., et al., *Studies on the substrate specificity of Escherichia coli galactokinase*. Org Lett, 2003. **5**(13): p. 2223–6.
2. Restituyo Jose, A., et al., *Conversion of aryl azides to O-alkyl imidates via modified Staudinger ligation*. Organic letters, 2003. **5**(23): p. 4357–60.
3. Rajski, S.R., L.R. Comstock, and S.G. Petersen, *Progress on the synthesis of functionally diverse aziridine-based cofactor mimetics*. American Association of Colleges of Pharmacy Annual Meeting, 2003. **104**(JUL): p. NIL_0270.
4. Martinez-Diaz, G.J., et al., *Mechanical and chemical analysis of gelatin-based hydrogel degradation*. Macromolecular Chemistry and Physics, 2003. **204**(15): p. 1898–1908.
5. Li, J. and W.J. Kao, *Synthesis of polyethylene glycol (PEG) derivatives and PEGylated-peptide biopolymer conjugates*. Biomacromolecules, 2003. **4**(4): p. 1055–67.
6. Kao, W.J. and Y. Liu, *Intracellular protein tyrosine phosphorylation of adherent human macrophages on adsorbed fibronectin*. Biomaterials, 2003. **24**(7): p. 1183–91.

7. Hoffmeister, D., et al., *Creation of the first anomeric D/L-sugar kinase by means of directed evolution*. Proc Natl Acad Sci U S A, 2003. **100**(23): p. 13184–9.
8. Fu, X., et al., *Antibiotic optimization via in vitro glycorandomization*. Nat Biotechnol, 2003. **21**(12): p. 1467–9.
9. Einerson, N.J., K.R. Stevens, and W.J. Kao, *Synthesis and physicochemical analysis of gelatin-based hydrogels for drug carrier matrices*. Biomaterials, 2003. **24**(3): p. 509–23.
10. Burmania, J.A., K.R. Stevens, and W.J. Kao, *Cell interaction with protein-loaded interpenetrating networks containing modified gelatin and poly(ethylene glycol) diacrylate*. Biomaterials, 2003. **24**(22): p. 3921–30.
11. Burmania, J.A., G.J. Martinez-Diaz, and W.J. Kao, *Synthesis and physicochemical analysis of interpenetrating networks containing modified gelatin and poly(ethylene glycol) diacrylate*. J Biomed Mater Res A, 2003. **67**(1): p. 224–34.
12. Albermann, C., et al., *Substrate specificity of NovM: implications for novobiocin biosynthesis and glycorandomization*. Org Lett, 2003. **5**(6): p. 933–6.
13. Adams, M.L. and G.S. Kwon, *Relative aggregation state and hemolytic activity of amphotericin B encapsulated by poly(ethylene oxide)-block-poly(N-hexyl-L-aspartamide)-acyl conjugate micelles: effects of acyl chain length*. J Control Release, 2003. **87**(1-3): p. 23–32.
14. Adams, M.L., D.R. Andes, and G.S. Kwon, *Amphotericin B encapsulated in micelles based on poly(ethylene oxide)-block-poly(L-amino acid) derivatives exerts reduced in vitro hemolysis but maintains potent in vivo antifungal activity*. Biomacromolecules, 2003. **4**(3): p. 750–7.

2002

1. Stevens, K.R., et al., *In vivo biocompatibility of gelatin-based hydrogels and interpenetrating networks*. J Biomater Sci Polym Ed, 2002. **13**(12): p. 1353–66.
2. Rich, D.H., M.G. Bursavich, and M.A. Estiarte, *Discovery of nonpeptide, peptidomimetic peptidase inhibitors that target alternate enzyme active site conformations*. Biopolymers, 2002. **66**(2): p. 115–25.
3. Park, Y., et al., *Effects of conjugated linoleic acid (CLA) metabolites and cognates in heparin-releasable lipoprotein lipase activity in 3T3-L1 adipocytes*. Faseb Journal, 2002. **16**(4): p. A224–A224.
4. Kao, W.J., J. Li, and D. Lok, *Bifunctional-modified hydrogels containing polyethylene glycol derivatives*. 2002, (Wisconsin Alumni Research Foundation, USA). Application: WO WO. p. 82 pp.

5. Goncalves, E. and T.D. Heath, *The effect of liposome size on lipoplex formation: The relationship between mixing and final lipid: DNA lipoplex ratios*. *Biophysical Journal*, 2002. **82**(1): p. 536A–536A.
6. Comstock, L.R. and S.R. Rajski, *Expeditious synthesis of aziridine-based cofactor mimics*. *Tetrahedron*, 2002. **58**(30): p. 6019–6026.
7. Bursavich, M.G. and D.H. Rich, *Designing Non-Peptide Peptidomimetics in the 21st Century: Inhibitors Targeting Conformational Ensembles*. *Journal of Medicinal Chemistry*, 2002. **45**(3): p. 541–558.
8. Brewer, M. and D.H. Rich, *Sequencing hydroxyethylamine-containing peptides via Edman degradation*. *Organic Letters*, 2002. **4**(20): p. 3469–72.
9. Adams, M.L. and G.S. Kwon, *The effects of acyl chain length on the micelle properties of poly(ethylene oxide)-block-poly(N-hexyl-L-aspartamide)-acyl conjugates*. *J Biomater Sci Polym Ed*, 2002. **13**(9): p. 991–1006.

2001

1. West, C.W., M.A. Estiarte, and D.H. Rich, *New Methods for Side-Chain Protection of Cysteine*. *Organic Letters*, 2001. **3**(8): p. 1205–1208.
2. Travins, J.M., et al., *Aspartic Protease Inhibitors: Expedient Synthesis of 2-Substituted Statines*. *Organic Letters*, 2001. **3**(17): p. 2725–2728.
3. Sok, D.E. and C.J. Sih, *Difference in susceptibility of tyrosine residue to oxidative iodination between a thioredoxin box region and a hormonogenic region*. *Archives of Pharmacal Research*, 2001. **24**(5): p. 446–454.
4. Ripka, A.S., et al., *Aspartic Protease Inhibitors Designed from Computer-Generated Templates Bind As Predicted*. *Organic Letters*, 2001. **3**(15): p. 2309–2312.
5. Rich, D.H., et al., *Merging Rational Drug Design with Combinatorial Chemistry: Reasonable and Unreasonable Expectations*. *Medicinal Chemistry into the Millennium*, ed. M.M. Campbell. 2001: I.S. Blagbrough Royal Society of Chemistry. 16–24.
6. Oost, T.K., C. Sukonpan, and D.H. Rich, *Design and synthesis of substrate based inhibitors of botulinum neurotoxin type B metalloprotease*. *Peptides 2000, Proceedings of the European Peptide Symposium, 26th, Montpellier, France, Sept. 10–15, 2000*, 2001: p. 23–25.
7. Kao, W.J., D. Lok, and J. Li, *Preparation of heterodifunctional polyethyleneglycols: network formation, characterization, and cell culture analysis*. *J Biomater Sci Polym Ed*, 2001. **12**(6): p. 599–611.

8. Estiarte, M.A., A.M. Elder, and D.H. Rich, *Synthetic progress towards a TMC-95 analog as a potential proteasome inhibitor*. Peptides: The Wave of the Future, Proceedings of the Second International and the Seventeenth American Peptide Symposium, San Diego, CA, United States, June 9–14, 2001, 2001: p. 532–533.
9. Dales, N.A., et al., *Design and Synthesis of Unsymmetrical Peptidyl Urea Inhibitors of Aspartic Peptidases*. Organic Letters, 2001. **3**(15): p. 2313–2316.
10. Bursavich, M.G., C.W. West, and D.H. Rich, *From Peptides to Non-Peptide Peptidomimetics: Design and Synthesis of New Piperidine Inhibitors of Aspartic Peptidases*. Organic Letters, 2001. **3**(15): p. 2317–2320.
11. Bursavich, M.G. and D.H. Rich, *Solid-Phase Synthesis of Aspartic Peptidase Inhibitors: 3-Alkoxy-4-Aryl Piperidines*. Organic Letters, 2001. **3**(17): p. 2625–2628.
12. Bursavich, M.G. and D.H. Rich, *Solution and solid phase synthesis of non-peptide peptidomimetic aspartic peptidase inhibitors*. Peptides: The Wave of the Future, Proceedings of the Second International and the Seventeenth American Peptide Symposium, San Diego, CA, United States, June 9–14, 2001, 2001: p. 537–538.
13. Brewer, M. and D.H. Rich, *Synthesis of a Tripeptide Derivative Containing the Phe-Arg Hydroxyethylene Dipeptide Isostere*. Organic Letters, 2001. **3**(6): p. 945–948.
14. Brewer, M. and D.H. Rich, *One-pot conversion of azides to protected guanidines via the Staudinger reduction; synthesis and utilization of the Phe-Arg hydroxyethylene dipeptide isostere*. Peptides: The Wave of the Future, Proceedings of the Second International and the Seventeenth American Peptide Symposium, San Diego, CA, United States, June 9–14, 2001, 2001: p. 40–41.